-
The Evolution of Pharma Depends on Data Integration and Application
The potential applications for this vast quantity and variety of data are nearly endless.
PAP-Q4-18-NI-001 -
The Coming of Age of Amorphous Solid Dispersions
Numerous drugs formulated as amorphous solid dispersions have been successfully commercialized.
PAP-Q4-18-CL-004 -
From Proof of Concept to Commercialization
Brammer’s vision is to be the leading CDMO for viral vector supply to cell and gene therapy innovators.
PAP-Q4-18-CL-003 -
Knowledge and Experience Equal Successful Technology Transfer
Technology transfer should result in the transfer of product and process knowledge into a new phase of the life cycle.
PAP-Q4-18-CL-008 -
A Turnkey Solution: Sourcing Equipment and Empowering Operators
We offer a turnkey solution by sourcing equipment that meets production line requirements.
PAP-Q4-18-CL-007 -
Designing Effective Facilities to Meet the Growing Demand for Oligonucleotide Drugs
An oligo drug manufacturing facility incorporates aspects of small-molecule and biologic drug facilities.
PAP-Q4-18-CL-002 -
Regulatory Spotlight: FDA Delays Enforcement of Serialization Mandate
The FDA issued new guidances regarding enforcement of the DSCSA's track and trace mandate.
PAP-Q4-18-NI-011 -
Big Data in Drug Development and Discovery
Companies that apply the data will have a competitive advantage in drug discovery and development.
PAP-Q4-18-NI-006 -
Big Data in Drug Manufacturing
To achieve cohesive data integration in drug manufacturing, systems must be aligned.
PAP-Q4-18-NI-005 -
Big Data in Drug Packaging and Distribution
The emphasis on serialization is a tangible move toward making post-market data mining more robust.
PAP-Q4-18-NI-004 -
Preparing Clinical Trial Logistics for a No-Deal Brexit
Pharmaceutical companies should prepare for Brexit by mitigating their supply chain risks.
PAP-Q4-18-CL-006 -
Drug Repositioning: Facilitating Drug Repositioning with Artificial Intelligence
Computer-based approaches are essential to enable systematic drug repositioning efforts.
PAP-Q4-18-NI-009 -
The Value of Complementary Specialized Capabilities
Continued investment in innovations that address the needs of current and next-generation therapies is essential.
PAP-Q4-18-CL-001 -
Risk Minimization with an Integrated Global Network
Collaborating with an embedded organization with an integrated, global network can facilitate access to growing markets.
PAP-Q4-18-CL-005 -
Preparative Chromatography
Servier’s InnoPreP™ technology offering appeals to mid-size pharmas who need to quickly move their project into clinical studies .
PAP-Q4-18-NI-002 -
New Drug News: Regulatory Approval Brings siRNA into the Rare Disease Toolbox
siRNA joins the other nucleic acid–based drugs entering the marketplace for the treatment of rare diseases.
PAP-Q4-18-NI-010 -
Foreign Investment: Chinese Capital Backs U.S. Biotech
Given the amount of Chinese capital and the growing interest in the segment, the market feels unlimited.
PAP-Q4-18-NI-008 -
Q: What Innovative Technologies Had the Greatest Impact on your Company this Year? What Were the Impacts?
Industry leaders discuss recent technological innovations.
PAP-Q4-18-NI-007 -
Q: Looking Forward, What New Technologies/Paradigms Do You Anticipate Having the Greatest Impact Next Year (Digitalization and Industry 4.0, Serialization, etc.)?
Industry leaders discuss forthcoming technological innovations.
PAP-Q4-18-NI-003
-
Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies
Oliver Technow, President of BioVectra, explains the necessity of forward-thinking CDMOs.
-
BioPharma CDMO Success Requires Technical Leadership and Problem-Solving Capabilities
As more antibody and other advanced therapies reach the commercialization stage, branded biologic and biosimilar development companies are increasingly turning to outsourcing partners, explains Federico Pollano, Senior Vice President Business Development for Rentschler Biotechnologie GmbH.
-
Building a Robust Supply Chain with Dependable Quality Primary Suppliers
Drug manufacturers and their suppliers face a number of challenges, such as downward pricing pressures and the need for flexibility and speed to market, says Dale Martin, General Manager & CFO for CapsCanada.
-
Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network
Gustavo Mahler, President & CEO of AGC Biologics discusses the increasing need for CDMO support to provide with advanced capabilities and technology platforms across scales and geographies.
President & CEOAGC Biologics -
Creating Value with Tailored ODT Solutions
Graeme MacLeod, Global Technical Development Manager at SPI Pharma, explains the benefits of ODT dosage forms.
-
Driving Change in the Pharma Industry and Biotech One Relationship at a Time
Syed T. Husain, Chief Commercial Officer and Catherine Hanley, Head of Marketing & Corporate Communications at Alcami Corporation discuss changing the industry’s mindset through relationships.
-
The Global Wearable Robotic Exoskeleton Market is Projected to Reach $5.4 Billion by 2028
The wearable exoskeleton market is projected to grow at a CAGR of 43.48%, during the forecast period from 2018 to 2028.
-
Pillar Biosciences Enters Strategic Partnership with China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia
Under the terms of the agreement, Pillar Biosciences will create a joint venture company with CBSH's subsidiary Central Laboratory (Holdings) Limited to provide precision diagnostic products and services to Hong Kong, Macau, South Korea and Southeast Asia.
-
Fujifilm Announces the Launch of Its Next Generation Apollo™ X Advanced Mammalian Expression System
Titres achieved are in excess of 10g/L without compromising product quality.
-
SightGlass Vision Multicenter Trial to Study Novel Eyeglasses to Control Nearsightedness for FDA Approval
CYPRESS currently enrolling children aged 6-9 at clinical sites throughout the U.S. and Canada.
-
Focused on Fermentation
Capua BioServices continues to invest to support modern fermentation, explains Elise Mous Director Sales & Marketing/Business Development and Thomas De Maria, Business Development Manager.
-
People, Expertise and Dedication are Key to Successful Strategic Partnerships
People and expertise drive the success of strategic partnerships, according to Elise Mous, Director of Sales & Marketing/Business Development at Capua Bioservices.
-
The Coming of Age of Amorphous Solid Dispersions
Márcio Temtem, Director for Drug Product Development at Hovione, discusses drug formulation using amorphous solid dispersions.
-
Procuring Equipment at the Speed of Business
Your equipment is the backbone of your entire facility, explains Adam Covitt, Vice President of Federal Equipment Company.
-
Hard-Shell Capsule Solutions for Sensitive Compounds: A Focus on Probiotics
Eli Elias, Director of Business Development for CapsCanada explains why hard-shell capsules designed to degrade under specific conditions are a better option for probiotics.
-
Fully Supporting Customer Needs for Biologics Development and Manufacturing
James Park, Senior Vice President and Global Head, Business Development Center for Samsung BioLogics discusses the construction of three state-of-the-art production facilities in the last seven years.
-
New Assays for Detecting Genomic Mutations Launched by Contextual Genomics
Hotspot assays detect genomic mutations in blood and solid tumors.
-
Initial Positive Results Lead to Expanded Cancer Trial
Deciphera Pharmaceuticals expands clinical trial for advanced malignancies to include patients with tenosynovial giant cell tumors (TGCTs).
-
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to be developed using Skyhawk's SkySTAR™ platform.
-
AstraZeneca Announces Organizational Changes
José Baselga, MD, PhD, appointed to head R&D for Oncology.
Nice Insight Awareness/Perception Scorecard
Research. Compare. Contact. Find the Ideal Partner.
Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.
- Search by company type, region, market segment and services.
- Select up to 5 companies to compare.
- View CA & CP performance scores against industry benchmark ratings.
Latest
View All LatestAddressing the Challenges and Opportunities Presented by Advanced Therapies
Jan 15, 2019 5:09:05 PM PAO-M01-19-NI_CL-001Researchers Identify Potential Approach for Treating the Toughest Breast Cancer
Jan 9, 2019 4:13:58 PM PAO-M01-19-NI-013New Assays for Detecting Genomic Mutations Launched by Contextual Genomics
Jan 8, 2019 10:58:34 AM PAO-M01-19-NI-005Remembering the Details: Partnering with an Equipment Supplier During a Merger or Acquisition
Jan 8, 2019 10:06:55 AM PAO-M01-19-CL-001
TOPICS
View All TopicsPRESS RELEASES
View All-
Flow Sciences, Inc. Partners with Three Companies to Contain Lyophilization Process of New HPAPI
Jan 15, 2019 4:55:35 PM -
The Global Wearable Robotic Exoskeleton Market is Projected to Reach $5.4 Billion by 2028
Jan 15, 2019 5:00:00 AM -
Abbott and "Malaria No More" Work Together to End Malaria in Odisha, India
Jan 14, 2019 5:00:00 AM -
New Opioid-alternative Raises $3.25 Million for Phase I Trials
Jan 14, 2019 5:00:00 AM
Nice Insight Industry Benchmark Reports 2017
Download Sample Report
